On June 26, 2024, the FDA approved ensifentrine (Ohtuvayre) for the treatment of COPD.
Molly Csere, PharmD
Advertisement
Articles by Molly Csere, PharmD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Drug Topics
1
Providers, Patients Show Favorable Perception of Remdesivir During COVID-19 Pandemic
2
Lower Baseline BMI Predicts Weight Loss At 6 Months With Liraglutide
3
Gaps Between Expectations and Effects on Long COVID Contribute to Trust in Vaccines
4
PCV21 Shows Cost Effectiveness Compared With PCV15, PCV13, and PPSV23
5
